Heinz Delesen - Concepedia

Author

Heinz Delesen

Bayer (Germany)

Also Known As

H. Delesen, Heinz Delesen

Publications

497

Citations

H-Index

Concepts

All Affiliations

Bayer (Germany)Bayer (United States)Sheba Medical Center Novartis (Switzerland)

About

Heinz Delesen is an author at Bayer (Germany) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	112
2	Pharmacology	3	3	69
3	Gastroenterology	1	1	24
4	Antimicrobial Pharmacokinetics	1	1	14
5	Cancer Therapeutics	1	1	20

Heinz Delesen

Publications

487

Citations

H-Index

Page 1

	Year	Citations
Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study Johannes Nagelschmitz, Stefan Willmann, Heinz Delesen, Clinical Drug Investigation	2013	86
Pharmacokinetics of moxifloxacin, a novel 8‐methoxy‐quinolone, in patients with renal dysfunction Dagmar Kubitza, Atef Halabi, Heinz Delesen British Journal of Clinical Pharmacology	2002	56
Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males Dagmar Kubitza, J. Möller, Heinz Delesen British Journal of Clinical Pharmacology	2005	45
Safety and Pharmacokinetics of Ciprofloxacin Dry Powder for Inhalation in Cystic Fibrosis: A Phase I, Randomized, Single-Dose, Dose-Escalation Study Heinz Delesen, Johannes Nagelschmitz, Doris Staab Journal of Aerosol Medicine and Pulmonary Drug Delivery	2014	45
Pharmacokinetic properties of BAY 81‐8973, a full‐length recombinant factor VIII Anita Shah, Heinz Delesen, Stephen J. Garger, Haemophilia	2015	40
Correlation between endogenous <scp>VWF</scp>:Ag and <scp>PK</scp> parameters and bleeding frequency in severe haemophilia <scp>A</scp> subjects during three‐times‐weekly prophylaxis with rFVIII‐<scp>FS</scp> Shadan Lalezari, U. Martinowitz, Jerzy Windyga, Haemophilia	2013	39
BAY 94‐9027, a PEGylated recombinant factor VIII, exhibits a prolonged half‐life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies Anita Shah, Thomas Coyle, Shadan Lalezari, Haemophilia	2018	39
Effects of Sucralfate on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers Uwe Schuhly, Jan-Georg M ller, Heinz Delesen Clinical Pharmacokinetics Pharmaceutical ScienceOral BioavailabilityNovel 8-MethoxyfluoroquinoloneHealthy VolunteersPharmacology	2001	35
Pharmacokinetics and Tissue Penetration of Moxifloxacin in??Intervention Therapy for Intra-Abdominal Abscess Andreas D. Rink, Heinz Delesen, Dagmar Kubitza, Clinical Drug Investigation Intra-abdominal AbscessAntimicrobial StewardshipTissue PenetrationGastroenterologySepsis	2008	24
Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial Ahmad Awada, Thierry Gil, Nicolas Whenham, The Journal of Clinical Pharmacology OncologySorafenib CombinedMg Bid SorafenibPharmacologyAdvanced Solid Tumors	2011	20

Page 1